Home › Crohn's Disease › California › San Francisco
Crohn's Disease clinical trials in San Francisco, CA
4 studies for Crohn's Disease are looking for participants at sites in and around San Francisco (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 2/3
- University of California San Francisco, San Francisco
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
RecruitingPhase 3
- UCSF Medical Center at Mission Bay, San Francisco
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
RecruitingPhase 4
- UCSF Benioff Children's Hospitals, San Francisco
Treatment of Moderate to Severe Refractory Crohn's Disease
RecruitingPhase 1/2
- University of California, San Francisco, San Francisco
About Crohn's Disease
Crohn's Disease can cause inflammation in any area from the mouth to the anus. Read about medicines, surgery or dietary management to treat symptoms.
More about Crohn's Disease on MedlinePlus
Crohn's Disease trials in other cities
- New York City, NY35 studies
- Boston, MA19 studies
- Miami, FL19 studies
- Cleveland, OH19 studies
- St. Louis, MO19 studies
- Tyler, TX17 studies
- Houston, TX17 studies
- Orlando, FL17 studies
- Atlanta, GA17 studies
- San Antonio, TX15 studies
- San Diego, CA15 studies
- Los Angeles, CA15 studies
Other studies in San Francisco
- Prostate Cancer45 studies
- Breast Cancer43 studies
- Non-Small Cell Lung Cancer36 studies
- Cancer (all types)35 studies
- Heart Failure29 studies
- Metastatic Cancer28 studies
- Lung Cancer22 studies
- Melanoma22 studies
- Pancreatic Cancer20 studies
- Ovarian Cancer19 studies
- Colorectal Cancer18 studies
- Cardiovascular Disease18 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.